Drugs Made In America Acquisition Corp. is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company has neither engaged in any operations nor generated any revenue to date. It is a shell company as defined under the Securities Exchange Act of 1934, with nominal assets consisting almost entirely of cash. The company issued founder shares to its sponsor, Drugs Made In America Acquisition LLC, and completed an initial public offering of units, along with a private placement of units to the sponsor. Proceeds from these offerings are held in a trust account for the benefit of public shareholders, to be used for the completion of an initial business combination or for the redemption of public shares if a combination is not completed within the specified period. The company has up to 15 months from the closing of the IPO to consummate an initial business combination, with the possibility of extensions. If unable to complete a business combination within the specified period, the company will redeem its public shares and seek to liquidate and dissolve.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Shell Companies Homepage dmaacorp.com
Sector Financial Services IR page —
Tags
blank check company, special purpose acquisition company, business combination, merger, share exchange, asset acquisition, recapitalization, reorganization, Drugs Made In America Acquisition LLC
Press page —

Metrics

Valuation  
Market cap $ 115.852M
Market cap (USD) $ 115.852M
P/E 22.47
PEG —
P/BV -13.79
P/S —
P/OCF -214.82
P/FCF -214.86
Dividend yield —
Turnover / mcap —
Returns  
ROE -81.8%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 6
Quality score -44.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Assets 239.919M 550.824K
Net profit 5.941M —
Free cash flow -539.187K —

Figure FY 2025 FY 2024
Share price 10.37 —
P/FCF -206.12 —

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Cash and deposits (USD) 1,351 6,137
Cash flow detail
Operating cash flow (USD) — -539,187
Change in payables (cash effect) (USD) — 144,904
Reported Mar 31, 2025 Apr 15, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On October 13, 2026, Drugs Made In America Acquisition Corp. (the “Company”) and Power Analytics Global Corp, a Delaware corporation (“PAGC”), entered into Amendment No. 1 (the “Amendment”) to their Amended and Restated Definitive Merger Agreement dated as of September 8, 2026 (the “Merger Agreement”). The Amendment was approved by the boards of directors of both parties.

Standalone Closing Valuation

The Merger Agreement provides for a Closing Valuation of US$2,850,000,000, determined on an asset basis and including PAGC’s proposed acquisition of APQC Inc and the UltraSolar intellectual property (the “APQC Acquisition”), and makes completion of the APQC Acquisition a condition to closing.

Background

As previously disclosed, on April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company” or “DMAA”), entered into a Definitive Merger Agreement (the “Original Agreement”) with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial intelligence, advanced analytics and quantum-resistant security solutions (“PAGC”). The Original Agreement was amended by Amendment No. 1 dated April 30, 2026, Amendment No. 2 dated April 30, 2026 and Omnibus Amendment No. 3 dated July 14, 2026 (together with the Original Agreement, the “Existing Agreement”). The Original Agreement, Amendment No. 1 and Amendment No. 2 were filed as Exhibits 2.1, 2.2 and 2.3 to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 5, 2026, and Omnibus Amendment No. 3 was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 20, 2026.

Amendment to Merger Agreement

As previously disclosed, on April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company” or “DMAA”), entered into a Definitive Merger Agreement (the “Merger Agreement”) with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial intelligence, advanced analytics and quantum-resistant security solutions (“PAGC”). As previously disclosed, the Merger Agreement was subsequently amended by Amendments No. 1 and No. 2. The Merger Agreement, as amended, provides for a business combination pursuant to which PAGC will merge with and into the Company (or a wholly-owned subsidiary of the Company, as may be mutually agreed by the parties), with the surviving entity continuing as the Company’s combined operating business following the closing (the “Merger”). Following the consummation of the Merger, the surviving entity is intended to operate as a publicly traded company on The Nasdaq Stock Market LLC.

Prompts

Drugs Made In America Acquisition Corp. (ticker DMAA), listed in United States.

Securities

Ticker Type Class Market Exchange Last price Price date
DMAA canonical Common share — US nasdaq 10.84 USD 2026-09-30
DMAAR Right — US nasdaq 0.12 USD 2026-09-30
DMAAU Unit — US nasdaq 10.93 USD 2026-09-30